Exagen to Announce Second Quarter 2024 Results on August 5, 2024
22 juil. 2024 09h00 HE
|
Exagen Inc.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before...
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
18 juil. 2024 19h08 HE
|
Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
09 juil. 2024 08h00 HE
|
Caribou Biosciences, Inc.
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences,...
Exagen Announces Campaign for Lupus Awareness Month
06 mai 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
04 avr. 2024 16h00 HE
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
09 mars 2024 12h00 HE
|
Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
06 mars 2024 08h00 HE
|
Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors – – Proceeds will support ongoing comprehensive mid to...
Immunology Collaboration and Licensing Agreements Analysis Report 2023
17 nov. 2023 06h13 HE
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
09 nov. 2023 16h05 HE
|
Exagen Inc.
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the...
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
08 nov. 2023 15h37 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...